Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

Impact · against what's priced in

Travere Therapeutics may see a valuation lift as new biomarker data suggests FILSPARI is disease-modifying rather than just symptom-managing. This expands the potential long-term market positioning and pricing power for the drug in treating IgA nephropathy.

TVTX+0.60: No priced-in read yet

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

What matters in this story

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

What matters in this story

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript

How each ticker is affected

Track these names every morning.

Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

Moderna leaked data was positive, what's hurting MRNA stock then?

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

What matters in this story

Next reads from the same story arc

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

What matters in this story

Next reads from the same story arc

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript

How each ticker is affected

Track these names every morning.

Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

Moderna leaked data was positive, what's hurting MRNA stock then?

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program